Use este identificador para citar ou linkar para este item: https://observatorio.fm.usp.br/handle/OPI/3166
Título: FRACTURE HEALING AND OSTEOPOROSIS AGENTS
Autor(es): SOUZA, Marcio Passini G.
Parte de: OSTEOPOROSIS INTERNATIONAL, v.23, suppl.4, p.S472-S472, 2012
Resumo: Abstract: Almost all drugs used for treatment and/or prevention of osteoporosis have also been studied concerning its action in the consolidation of fractures. Herbert Fleich1, the creator of modern bisphosphonates (BPs), in 2001, pointed a possible injury to the consolidation of fractures with use of BPs. That’s because the action of osteoclast in the first phase of the consolidation of fractures2 . The use of BPs, or any other antiresorptive drugs (ARDs) at this stage should be harmful to the consolidation. However, nowadays we know that many ARDs, including BPs, accelerate the formation of fracture callus, it means, the consolidation. As for the repair of fracture callus, there are drugs that accelerate, as the bone anabolic drugs (BADs) and drugs that slow down, as ARDs. That ’ s because in this fracture repair phase, the primary callus is reabsorbed by action of osteoclasts. The inhibition of osteoclasts activity, at this stage, slows down bone remodeling. But what really matters is whether the callus formed is enough to resist efforts. We still don't know everything about how the interaction between drugs and the natural process of consolidation and repair of fractures happens , but many facts are already known. We know that the most modern drugs are active both in the consolidation of fractures as in better orthopedic implant anchorage. We know that, in the healing processes of fractures, there are cartilaginous and membranous phases which repeat the process of cortical and lamellar bone formation and bone remodeling3 . Thus, drugs that act in the process of ossification and remodeling of the skeleton have great potential to act in the consolidation of fractures. The author will present here studies of consolidation of fractures with the use of antiosteoporotics agents. The BPs retards the repairing of final callus, but increases the volume of primary callus, enhancing their mechanical resistance. On the other hand, teriparatide and strontium ranelate accelerates the formation of primary fracture callus, the remodeling of mature bone callus, and improves the biomechanical properties of bone fractured both in animals and in clinical studies.
Aparece nas coleções:

Comunicações em Eventos - HC/IOT
Instituto de Ortopedia e Traumatologia - HC/IOT


Arquivos associados a este item:
Não existem arquivos associados a este item.

Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.